Have you been diagnosed with esophageal or gastric cancer that has spread to a number of places in your body? If the cancer has spread to 1–3 places, you have what is called oligometastatic esophageal or gastric cancer, and you may be able to participate in this study of a potential new treatment.

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients with Esophageal and Gastric Cancer that has Spread

**WHY consider participating in this study?**

- Research studies are an important way to test the effectiveness of new therapies and approaches for treating esophageal and gastric cancer.
- The usual treatment approach (the standard care most people get for oligometastatic esophageal and gastric adenocarcinoma) is treatment with Food and Drug Administration (FDA)-approved chemotherapy called FOLFOX (using the drugs leucovorin, 5-fluorouracil [5-FU], and oxaliplatin) or CAPOX (using the drugs capecitabine and oxaliplatin). More recently, an immunotherapy drug, nivolumab, has also been approved by the FDA in addition to chemotherapy, and it is now part of standard treatment.
- EA2183 aims to determine 1) if adding radiotherapy to the usual combination of drugs used to treat the kind of cancer you have will help you live longer, and 2) if this new approach is better or worse than the usual approach used to treat esophageal cancer or gastric adenocarcinoma.

**WHAT does this study involve?**

- If you decide to take part in this study, you will receive standard treatment (i.e., FOLFOX or CAPOX, with or without nivolumab) as decided by your doctor, for about four months. Then you will be assigned by chance (randomized) to one of two groups:
  - **Group 1:** You will receive radiation therapy and continue your prior standard treatment for up to 2 years.
  - **Group 2:** You will continue to receive the standard treatment alone for up to 2 years.
- Each patient has a 2/3 chance of being in Group 1 and a 1/3 chance of being in Group 2.

*Patients are also able to register to EA2183 at the randomization step, after they have started first-line standard treatment. They would enroll after completion of 4 months of treatment, if their tumors have not progressed.*
After you finish your study treatment, your doctor will continue to see you every 3 months for the first 2 years. Then, you will be seen every 6 months for up to 5 years. These post-study visits are routine clinic visits that patients with metastatic esophageal and gastric adenocarcinoma usually have.

**WHO will take part in this study?**

- Approximately 314 people diagnosed with esophageal or gastric cancer that has spread will begin this study, and then study participants whose cancer is not growing will continue and will be assigned to Group 1 or Group 2.
- You can decide to stop taking part in the study at any time, even after you have enrolled.

**WHAT are the costs of taking part in this study?**

- Just as you would if you were getting the usual care for your cancer, you and/or your insurance plan will need to pay for some or all of the costs of medical care you get as part of this study. Check with your insurance company to find out what they will pay for.

**IF you would like to know more**

- About the EA2183 study, talk with your doctor, or:
  - Visit [www.ecog-acrin.org](http://www.ecog-acrin.org) and search EA2183, then select the link to EA2183
    - For information about medical facilities where the study is available, scroll down the page to Locations and Contacts
  - Call the NCI Cancer Information Service at 1-800-4-CANCER (1-800-422-6237)
- About clinical trials:
  - General cancer information: visit the NCI website at [www.cancer.gov](http://www.cancer.gov)
- About ECOG-ACRIN:
  - Visit [www.ecog-acrin.org](http://www.ecog-acrin.org)
  - For a list of patient resources and links to patient advocacy groups, visit [https://ecog-acrin.org/patients/resources](https://ecog-acrin.org/patients/resources)